EP4217001A4 - Compositions et méthodes de prévention et de traitement de lésion cutanée radique - Google Patents

Compositions et méthodes de prévention et de traitement de lésion cutanée radique Download PDF

Info

Publication number
EP4217001A4
EP4217001A4 EP21873367.3A EP21873367A EP4217001A4 EP 4217001 A4 EP4217001 A4 EP 4217001A4 EP 21873367 A EP21873367 A EP 21873367A EP 4217001 A4 EP4217001 A4 EP 4217001A4
Authority
EP
European Patent Office
Prior art keywords
preventing
treatment
composition
radiation damage
skin radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21873367.3A
Other languages
German (de)
English (en)
Other versions
EP4217001A1 (fr
Inventor
Reginald L. HARDY
Mitchell Brigell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rythera Therapeutics Inc
Original Assignee
Rythera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rythera Therapeutics Inc filed Critical Rythera Therapeutics Inc
Publication of EP4217001A1 publication Critical patent/EP4217001A1/fr
Publication of EP4217001A4 publication Critical patent/EP4217001A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21873367.3A 2020-09-22 2021-09-22 Compositions et méthodes de prévention et de traitement de lésion cutanée radique Pending EP4217001A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081718P 2020-09-22 2020-09-22
US202063081547P 2020-09-22 2020-09-22
PCT/US2021/051583 WO2022066791A1 (fr) 2020-09-22 2021-09-22 Compositions et méthodes de prévention et de traitement de lésion cutanée radique

Publications (2)

Publication Number Publication Date
EP4217001A1 EP4217001A1 (fr) 2023-08-02
EP4217001A4 true EP4217001A4 (fr) 2024-04-24

Family

ID=80857195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21873367.3A Pending EP4217001A4 (fr) 2020-09-22 2021-09-22 Compositions et méthodes de prévention et de traitement de lésion cutanée radique

Country Status (7)

Country Link
EP (1) EP4217001A4 (fr)
JP (1) JP7673210B2 (fr)
AU (2) AU2021349237B2 (fr)
CA (1) CA3193398A1 (fr)
IL (1) IL301530A (fr)
MX (1) MX2023003357A (fr)
WO (1) WO2022066791A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022351983A1 (en) * 2021-09-22 2024-04-18 Rythera Therapeutics Inc. Composition and method for prevention and treatment of cutaneous radiation injury
CN120091820A (zh) * 2022-09-22 2025-06-03 瑞特拉治疗公司 用于预防和治疗皮肤放射性损伤的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19621038A1 (de) * 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
ATE337003T1 (de) 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
PT2114896E (pt) * 2006-12-21 2015-11-04 Peter Maccallum Cancer Inst Compostos radio-protetores e métodos relacionados
US20090156982A1 (en) * 2007-09-06 2009-06-18 Arezou Petrie Transdermal treatment device and method
US9616006B2 (en) * 2007-10-10 2017-04-11 DermaMedics, LLC Methods and compositions for treating dermatological diseases and conditions
US20150353912A1 (en) * 2012-05-31 2015-12-10 Children's Hospital Medical Center Methods for treating and preventing radiation injury using activated protein c polypeptides
WO2016142341A1 (fr) 2015-03-06 2016-09-15 Repoceuticals Aps Mélatonine pour la prévention et le traitement de la vaginite et de la rectite radiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Doxepin rinse for oral mucositis", DENTAL ABSTRACTS, MOSBY, ST. LOUIS, MO, US, vol. 54, no. 1, 1 January 2009 (2009-01-01), pages 54 - 55, XP025891715, ISSN: 0011-8486, [retrieved on 20090127], DOI: 10.1016/J.DENABS.2008.08.049 *
BERGER BERNHARD ET AL: "Severe skin reaction secondary to concomitant radiotherapy plus cetuximab", RADIATION ONCOLOGY, BIOMED CENTRAL LTD, LO, vol. 3, no. 1, 28 January 2008 (2008-01-28), pages 5, XP021039595, ISSN: 1748-717X *
KAWASHITA YUMIKO ET AL: "Oral management strategies for radiotherapy of head and neck cancer", JAPANESE DENTAL SCIENCE REVIEW, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 1, 20 February 2020 (2020-02-20), pages 62 - 67, XP086387121, ISSN: 1882-7616, [retrieved on 20200220], DOI: 10.1016/J.JDSR.2020.02.001 *
LALEH SHARIATI ET AL: "Protective effects of doxepin cream on radiation dermatitis in breast cancer: A single arm double-blind randomized clinical trial", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 86, no. 9, 25 February 2020 (2020-02-25), pages 1875 - 1881, XP071603255, ISSN: 0306-5251, DOI: 10.1111/BCP.14238 *
LEE JEFFREY K ET AL: "ASGE guideline on the role of endoscopy for bleeding from chronic radiation proctopathy", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 90, no. 2, 22 June 2019 (2019-06-22), pages 171, XP085743421, ISSN: 0016-5107, [retrieved on 20190622], DOI: 10.1016/J.GIE.2019.04.234 *
See also references of WO2022066791A1 *

Also Published As

Publication number Publication date
IL301530A (en) 2023-05-01
WO2022066791A1 (fr) 2022-03-31
AU2025202935A1 (en) 2025-05-15
MX2023003357A (es) 2023-06-30
AU2021349237A1 (en) 2023-06-08
AU2021349237B2 (en) 2025-05-01
JP7673210B2 (ja) 2025-05-14
JP2023544448A (ja) 2023-10-23
EP4217001A1 (fr) 2023-08-02
CA3193398A1 (fr) 2022-03-31

Similar Documents

Publication Publication Date Title
EP4415755A4 (fr) Compositions ciblant ace2 et méthodes de traitement de la covid-19
EP3934615A4 (fr) Compositions et méthodes de traitement de l'acné
EP4185333A4 (fr) Composition et méthode pour traiter des maladies oculaires
EP4518846A4 (fr) Compositions et méthodes de traitement de l'épilepsie
EP4171606A4 (fr) Compositions et méthodes de traitement de la covid-19
EP4516305A4 (fr) Procédé et composition pour prévenir ou traiter la myopie
EP4217001A4 (fr) Compositions et méthodes de prévention et de traitement de lésion cutanée radique
EP4114411A4 (fr) Compositions et méthodes pour le traitement du cancer du pancréas
EP3982999C0 (fr) Composition et méthode de traitement d'une lésion tissulaire hépatique
EP4518924A4 (fr) Système et procédé de traitement pour foetus prématuré
EP4373520A4 (fr) Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci
EP4405044A4 (fr) Compositions et méthodes de prévention et de traitement de lésion cutanée radique
EP4103177A4 (fr) Compositions et méthodes pour le traitement et/ou la prévention de maladies oculaires
EP4623299A4 (fr) Méthode et traitement
EP4415770A4 (fr) Compositions échogènes et leurs méthodes d'utilisation pour le traitement de la douleur
EP4415737A4 (fr) Compositions et méthodes de traitement d'affections cutanées
EP4408532A4 (fr) Compositions et méthodes pour le traitement des troubles associés à pcdh19
EP4323063A4 (fr) Compositions et procédés utiles pour le traitement de la leucodystrophie h-abc
EP4395844A4 (fr) Compositions et méthodes destinées au traitement de fractures osseuses
EP4370654A4 (fr) Compositions et méthodes pour traiter une maladie
EP4463116A4 (fr) Shunt et procédé pour traiter le glaucome
EP4175627A4 (fr) Composition et procédé de traitement d'infections
EP4118210A4 (fr) Traitement du covid-19 et procédés correspondants
EP4149436A4 (fr) Compositions et procédés de traitement de plaies
EP4164563A4 (fr) Shunt et procédé pour traiter le glaucome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0041000000

Ipc: A61K0031135000

A4 Supplementary search report drawn up and despatched

Effective date: 20240326

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20240320BHEP

Ipc: A61K 9/02 20060101ALI20240320BHEP

Ipc: A61K 9/00 20060101ALI20240320BHEP

Ipc: A61P 43/00 20060101ALI20240320BHEP

Ipc: A61P 17/02 20060101ALI20240320BHEP

Ipc: A61K 41/00 20200101ALI20240320BHEP

Ipc: A61K 31/135 20060101AFI20240320BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251209